MedPath

The control and prevention of type 2 diabetes by the inhibition of adipose tissue inflammation through Diacerei

Not Applicable
Completed
Conditions
Patients aged 40â€65 years who had type 2 Diabetes for at least 2 years since diagnosis with a glycated haemoglobin (HbA1c) level of 7.5%â€10%
type 2 Diabetes who had inadequate glycaemic control
Registration Number
TCTR20200820004
Lead Sponsor
/A
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
35
Inclusion Criteria

Type 2 Diabetes for at least 2 years since diagnosis with a glycated haemoglobin (HbA1c) level of 7.5%â€10%

Exclusion Criteria

Patients who had chronic inflammatory disease, chronic steroid use, serum creatinine level >2 mg/dL or eGFR <60 ml/min/1.73 m2/day, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels more than three times the upper normal limit

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The glucose&#45;lowering effect of low&#45;dose diacerein and its responsiveness metabolic markers in uncont 2 year performance liquid chromatography coupled to an accurate&#45;mass quadrupole time&#45;of&#45;flight mass spectro,Metabolic biomarkers for coronary artery disease in inadequately controlled type 2 Diabetes 2 year performance liquid chromatography coupled to an Agilent 6540 UHD accurate&#45;mass quadrupole time&#45;of&#45;fl,The glucose&#45;lowering effect of low&#45;dose diacerein and its responsiveness metabolic markers in uncont 2 year performance liquid chromatography coupled to an Agilent 6540 UHD accurate&#45;mass quadrupole time&#45;of&#45;fl,The glucose&#45;lowering effect of low&#45;dose diacerein and its responsiveness metabolic markers in uncont 2 year performance liquid chromatography coupled to an Agilent 6540 UHD accurate&#45;mass quadrupole time&#45;of&#45;fl
Secondary Outcome Measures
NameTimeMethod
none none none
© Copyright 2025. All Rights Reserved by MedPath